Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E.
Möllgård L, et al. Among authors: gronbaek k.
Haematologica. 2011 Jul;96(7):963-71. doi: 10.3324/haematol.2010.039669.
Haematologica. 2011.
PMID: 21719884
Free PMC article.
Clinical Trial.